Michael Weiss
Directeur Général chez TG THERAPEUTICS, INC.
Fortune : 235 M $ au 30/06/2024
Profil
M. Michael S. Weiss est président du conseil d'administration de Checkpoint Therapeutics, Inc. et président exécutif de Mustang Bio, Inc. et associé d'Opus Point Partners Management LLC, associé et gestionnaire de portefeuille d'Opus Point Partners LLC et président exécutif, président et PDG de TG Therapeutics, Inc. Il siège au conseil d'administration de Cyprium Therapeutics, Inc, Fortress Biotech, Inc, Caelum Biosciences, Inc, Cellvation, Inc et Helocyte, Inc. M. Weiss a été précédemment employé en tant que président du conseil d'administration de National Holdings Corp, directeur non exécutif d'Avenue Therapeutics, Inc. et coprésident de CB Pharma Acquisition Corp, président exécutif de IASO Pharma, Inc. et président non exécutif de National Holdings Corp, président de XTL Biopharmaceuticals Ltd, président et directeur général de Keryx Biopharmaceuticals, Inc, président et directeur général d'ACCESS Oncology, Inc, président de Paligent, Inc, administrateur de Cancer Care, Inc, et avocat de Cravath, Swaine & Moore LLP. Il a également été membre du conseil d'administration de Healthcare Integrated Services, Inc. et de Genta, Inc. Il a obtenu son diplôme de premier cycle à l'Université d'État de New York à Albany et un diplôme de deuxième cycle à la Columbia Law School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
TG THERAPEUTICS, INC.
8,46% | 17/04/2024 | 13 074 929 ( 8,46% ) | 233 M $ | 30/06/2024 |
FORTRESS BIOTECH, INC.
6,60% | 27/03/2024 | 1 346 985 ( 6,60% ) | 2 M $ | 30/06/2024 |
| 14/05/2024 | 112 174 ( 0,31% ) | 241 174 $ | 30/06/2024 | |
MUSTANG BIO, INC.
0,05% | 27/06/2024 | 16 303 ( 0,05% ) | 7 711 $ | 30/06/2024 |
Postes actifs de Michael Weiss
| Sociétés | Poste | Début |
|---|---|---|
| TG THERAPEUTICS, INC. | Directeur Général | 29/12/2011 |
| FORTRESS BIOTECH, INC. | Directeur/Membre du Conseil | 20/12/2013 |
| CHECKPOINT THERAPEUTICS, INC. | Président | 13/10/2015 |
| MUSTANG BIO, INC. | Président | 01/05/2015 |
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Fondateur | 01/01/2017 |
| Cellvation, Inc. | Directeur/Membre du Conseil | - |
Helocyte, Inc.
 Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Opus Point Partners LLC
 Opus Point Partners LLC Financial ConglomeratesFinance Opus Point Partners LLC was founded in 2009 and is headquartered in New York, NY. | Fondateur | 01/01/2009 |
Baergic Bio, Inc.
 Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Michael Weiss
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Weiss
| State University of New York at Albany | Undergraduate Degree |
| Columbia Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| FORTRESS BIOTECH, INC. | Health Technology |
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
| AVENUE THERAPEUTICS, INC. | Health Technology |
| MUSTANG BIO, INC. | Health Technology |
| Entreprise privées | 18 |
|---|---|
| Paligent, Inc. | Finance |
National Holdings Corp.
 National Holdings Corp. Investment Banks/BrokersFinance National Holdings Corp. engages in the provision of investment banking and asset management services. It operates through the following segments: Brokerage and Advisory Services and Tax and Accounting Services. The Brokerage and Advisory Services segment includes broker-dealer and investment advisory services, sale of insurance products and licensed mortgage brokerage services. The Tax and Accounting Services segment involves tax preparation and accounting services provided by National Tax. The company was founded in 1947 and is headquartered in New York, NY. | Finance |
Healthcare Integrated Services, Inc.
 Healthcare Integrated Services, Inc. Medical/Nursing ServicesHealth Services Healthcare Integrated Services, Inc. is a multi-disciplinary provider of healthcare services, specializing in diagnostic imaging, physician management and consulting services, and clinical research trials. It presently operates seven diagnostic imaging facilities and provides exclusive management, consulting and/or clinical research services to several physician practices in New Jersey. The Company currently operates in two industry segments those are Diagnostic imaging, Physician Management/Consulting and Clinical Research. The Company also manages, through a joint venture, a network of radiology facilities in New Jersey, presently consisting of facilities. Through this joint venture, the Company provides services to automobile insurance carriers in New Jersey. Healthcare Integrated Services, Inc. was founded in 1991 and is headquartered in Ocean, NJ. | Health Services |
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
ACCESS Oncology, Inc.
 ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Health Technology |
Genta, Inc.
 Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Health Technology |
IASO Pharma, Inc.
 IASO Pharma, Inc. Pharmaceuticals: MajorHealth Technology IASO Pharma, Inc. operated as a development stage biopharmaceutical company which focused on acquiring, developing and commercializing drugs for the treatment and prevention of infectious diseases and other serious illnesses. The company was founded on October 5, 2006 and is headquartered in San Diego, CA. | Health Technology |
Cravath, Swaine & Moore LLP
 Cravath, Swaine & Moore LLP Miscellaneous Commercial ServicesCommercial Services Cravath, Swaine & Moore LLP provides legal services. The firm's practice areas encompasses corporate, executive compensation and benefits, international business, litigation, pro bono, tax, and trusts and estates. Its lawyers and associates' training focus on addressing and handling clients' legal issues, business transaction, and disputes. The company was founded in 1819 and is headquartered in New York, NY. | Commercial Services |
Cancer Care, Inc.
 Cancer Care, Inc. Hospital/Nursing ManagementHealth Services Cancer Care, Inc. provides cancer treatment services. The firm's services include counseling and support groups, education, financial assistance and practical help. The company was founded in 1944 and is headquartered in New York, NY. | Health Services |
Opus Point Partners Management LLC
 Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Finance |
Origo Acquisition Corp.
 Origo Acquisition Corp. Financial ConglomeratesFinance Origo Acquisition Corp. is a blank check company. It seeks to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company was founded on August 26, 2014 and is headquartered in New York, NY. | Finance |
| Checkpoint Therapeutics, Inc. | |
Opus Point Partners LLC
Opus Point Partners LLC Financial ConglomeratesFinance Opus Point Partners LLC was founded in 2009 and is headquartered in New York, NY. | Finance |
Helocyte, Inc.
Helocyte, Inc. Miscellaneous Commercial ServicesCommercial Services Helocyte, Inc. engages in the development and commercialization of immunotherapies for the prevention and treatment of cytomegalovirus or CMV (cancer and infectious disease). It focuses on developing PepVax, a HLA-restricted single antigen peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant recipients and Triplex. The company was founded by Donald J. Diamond in 2015 and is headquartered in New York, NY. | Commercial Services |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Commercial Services |
| Cellvation, Inc. | |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | Health Technology |
